Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report

Frontiers in Oncology 2026 Open access

Read full text
Authors: Chelsey M. Williams, Susanne M. Arnold, John L. Villano, Erika N. Amarilla Alonso, Christine F. Brainson, Paul Otto Schwarzenberger, Sahista Vahora, Ayman Qasrawi, Reinhold Munker, B. Mark Evers, Zhonglin Hao
DOI: 10.3389/fonc.2026.1885732
Cited by: 1
References: 6

Abstract

Novel CAR-T therapies targeting delta-like ligand 3 (DLL-3) are promising treatment strategies for individuals with extensive-stage SCLC (ES-SCLC). We report a case of a patient with ES-SCLC who received investigational therapy LB2102 off-label after becoming ineligible for a clinical trial. We described her positive, long-term response to treatment. This case highlights efficacious use of this investigational drug in a real-world setting prior to release of final reported data from phase 1 trial NCT05680922.

Fields of Study & Subjects

CAR-T cell therapy research Lung Cancer Research Studies Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Frontiers in Oncology
Publisher
Frontiers Media SA
Volume
16
Pages
1885732–1885732
Publication date
7 July 2026
Language
EN